Succinivibrionaceae is dominant family in fecal microbiota of Behçet's Syndrome patients with uveitis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
01
2020
accepted:
19
10
2020
entrez:
30
10
2020
pubmed:
31
10
2020
medline:
5
1
2021
Statut:
epublish
Résumé
Behçet's Syndrome (BS) is a multisystem vasculitis with various clinical manifestations. Pathogenesis is unclear, but studies have shown genetic factors, innate immunity and autoinflammation to have an important role in the disease course. Diversity in the microbial community of gut microbiota may significantly contribute to the activation of the innate immune system. The clinical features of BS present themselves in clusters and each cluster may be a consequence of different disease mechanisms. For this reason we aimed to investigate the gut microbiota of BS patients with uveitis. In addition to healthy controls, we have aimed to compare the gut microbiota of BS with that of Familial Mediterranean Fever (FMF) and Crohn's Disease (CD) as both diseases have innate and autoinflammatory features in their pathogenesis. Seven patients with BS, 12 patients with FMF, 9 patients with CD and 16 healthy controls (HC) were included in the study. Total genomic DNAs were isolated from fecal samples of the patients. Partial 16S rRNA gene was sequenced using the PGM Ion Torrent (Thermo Fisher Scientific, Waltham, MA, USA) for microbiota analysis. Statistical analysis showed that significant differences were detected on the microbial community of four groups. Succinivibrionaceae is dominant and the signature family, whereas Bacteroides was absent in BS patients.
Identifiants
pubmed: 33125440
doi: 10.1371/journal.pone.0241691
pii: PONE-D-19-35822
pmc: PMC7598488
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0241691Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Clin Exp Rheumatol. 2005 Jul-Aug;23(4 Suppl 38):S81-5
pubmed: 16273771
J Immunol Res. 2019 Sep 12;2019:7371458
pubmed: 31612152
Autoimmun Rev. 2015 Apr;14(4):269-76
pubmed: 25435420
Mod Rheumatol. 2019 Mar;29(2):357-362
pubmed: 29583036
J Rheumatol. 2002 Nov;29(11):2393-6
pubmed: 12415598
Arthritis Rheumatol. 2017 May;69(5):964-975
pubmed: 27863183
J Rheumatol. 1993 Sep;20(9):1544-9
pubmed: 8164212
Oral Dis. 2006 May;12(3):271-7
pubmed: 16700735
Clin Immunol. 2016 Aug;169:28-35
pubmed: 27283393
J Rheumatol. 2005 Feb;32(2):287-91
pubmed: 15693089
Trends Biotechnol. 2015 Sep;33(9):496-503
pubmed: 26210164
Adv Med Sci. 2017 Sep;62(2):414-420
pubmed: 28711782
Best Pract Res Clin Rheumatol. 2018 Apr;32(2):261-270
pubmed: 30527431
Front Immunol. 2019 Dec 06;10:2830
pubmed: 31921115
Acta Ophthalmol (Copenh). 1992 Dec;70(6):786-9
pubmed: 1488888
J Oral Microbiol. 2015 Jun 01;7:27150
pubmed: 26037240
J Clin Med. 2017 Jun 09;6(6):
pubmed: 28598360
World J Gastroenterol. 2012 Feb 7;18(5):412-24
pubmed: 22346247
Oral Microbiol Immunol. 2005 Jun;20(3):167-71
pubmed: 15836518
J Ophthalmic Vis Res. 2013 Jul;8(3):291-3
pubmed: 24349676
J Periodontol. 1999 Dec;70(12):1449-56
pubmed: 10632520
Nat Genet. 2010 Aug;42(8):703-6
pubmed: 20622879
Scand J Rheumatol. 2005;34(1):56-8
pubmed: 15903027
Rheumatology (Oxford). 2006 Dec;45(12):1461-5
pubmed: 16998234
Clin Exp Rheumatol. 2019 Nov-Dec;37 Suppl 121(6):58-66
pubmed: 31172918
Microb Genom. 2016 Feb 9;2(2):e000043
pubmed: 28348841
Clin Exp Immunol. 2018 Jan;191(1):11-18
pubmed: 28898393
Clin Rheumatol. 2019 May;38(5):1437-1445
pubmed: 30628011
J Immunol Res. 2017;2017:6836498
pubmed: 28835902
Microbiome. 2018 Aug 4;6(1):135
pubmed: 30077182
Genome Announc. 2017 Sep 14;5(37):
pubmed: 28912310
Nat Genet. 2017 Mar;49(3):438-443
pubmed: 28166214
Semin Immunopathol. 2015 Jul;37(4):413-8
pubmed: 26068404
Pediatr Rheumatol Online J. 2017 Apr 20;15(1):33
pubmed: 28427473
Arthritis Rheumatol. 2016 Nov;68(11):2646-2661
pubmed: 27333153
Clin Exp Rheumatol. 2009 Mar-Apr;27(2 Suppl 53):S32-6
pubmed: 19796530
Front Immunol. 2017 Sep 15;8:1107
pubmed: 28966614
PLoS One. 2017 Sep 20;12(9):e0184789
pubmed: 28931089
Arthritis Rheum. 1997 Oct;40(10):1879-85
pubmed: 9336425
Nat Genet. 2010 Dec;42(12):1118-25
pubmed: 21102463
J Ophthalmol. 2018 Apr 26;2018:9518065
pubmed: 29854430
Ann Rheum Dis. 2004 Nov;63(11):1450-2
pubmed: 15479894
Front Immunol. 2019 Mar 29;10:665
pubmed: 30984205
Intern Emerg Med. 2019 Aug;14(5):677-689
pubmed: 30747365
Gene. 2013 Nov 1;530(1):100-3
pubmed: 23973724
Rheumatology (Oxford). 2020 May 1;59(Supplement_3):iii101-iii107
pubmed: 32348523
Clin Exp Rheumatol. 2016 Sep-Oct;34(6 Suppl 102):82-85
pubmed: 27791948
PLoS One. 2016 Apr 22;11(4):e0153746
pubmed: 27105322
Lancet. 1990 May 5;335(8697):1078-80
pubmed: 1970380
Genome Biol. 2017 Jul 27;18(1):142
pubmed: 28750650